Onward Medical H1 2026 Revenue Hits EUR4.2M as ARC-EX Sales Jump Fivefold; Cash Runway to 2028

The Quick Take

• Onward Medical posted EUR4.2 million in H1 2026 revenue, fueled by a fivefold jump in ARC-EX system sales.
• The company raised over EUR40 million in fresh equity, extending its cash runway to 2028 at EUR81.5 million.
• ARC-EX spinal cord stimulation technology is driving accelerating commercial adoption in the medical device space.

Synthesized from 1 source — full coverage, sentiment breakdown, and forward signals below.

Onward Medical NV, a medical device company focused on spinal cord stimulation therapy, posted EUR4.2 million in first-half 2026 revenue driven by a fivefold jump in its ARC-EX system sales. The company simultaneously secured over EUR40 million in fresh equity, pushing its total cash runway to EUR81.5 million and providing capital runway through 2028. This combination of accelerating commercial traction and a substantial equity buffer positions Onward as a high-growth pre-profitability medical device play, though the EUR4.2 million revenue against EUR81.5 million cash highlights how far commercial scale still needs to advance.

Onward operates in the spinal cord stimulation segment, competing with established players like Medtronic, Boston Scientific, and Abbott, which collectively dominate the neuromodulation market. The ARC-EX system's fivefold sales surge suggests genuine clinical uptake, but the absolute revenue figure remains small relative to sector leaders. For investors in small-cap medical devices, the cash runway extension is a positive de-risking signal — eliminating near-term dilution risk while commercial traction builds. The fresh EUR40 million equity raise also implies investor confidence in the ARC-EX platform's differentiation.

Forward signals to monitor include Onward's H2 2026 revenue cadence to gauge whether the fivefold ARC-EX growth rate is sustainable or front-loaded, clinical trial outcomes for expanded ARC-EX indications, and any partnership or licensing announcements with larger medtech platforms. The macro variable is reimbursement policy evolution — whether European and US payers broaden coverage for spinal cord stimulation therapy will determine how quickly ARC-EX can scale beyond early adopter centers into mainstream hospital procurement.